Gideon Gross active positions
| Companies | Position | Start | End |
|---|---|---|---|
GentiBio, Inc.
 GentiBio, Inc. BiotechnologyHealth Technology GentiBio, Inc. engages in the development of engineered regulatory T cells (EngTregs) programmed to treat autoimmune, alloimmune, autoinflammatory, and allergic diseases. The company was founded by Adel Nada, David Rawlings, Jane H. Buckner, and Gideon Gross and is headquartered in Seattle, WA. | Founder | - | - |
Career history of Gideon Gross
Former positions of Gideon Gross
| Companies | Position | Start | End |
|---|---|---|---|
ImmPACT-Bio Ltd.
 ImmPACT-Bio Ltd. BiotechnologyHealth Technology ImmPACT-Bio Ltd. develops therapies to treat cancer. Its chimeric antigen receptor T-cell (CAR-T) therapy addresses the need to differentiate cancerous from non-cancerous tissues. The company was founded by Gideon Gross in April 2017 and is headquartered in Nes Ziona, Israel. | Founder | 16/11/2016 | - |
Statistics
International
| Israel | 2 |
| United States | 2 |
Operational
| Founder | 2 |
Sectoral
| Health Technology | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Private companies | 2 |
|---|---|
ImmPACT-Bio Ltd.
ImmPACT-Bio Ltd. BiotechnologyHealth Technology ImmPACT-Bio Ltd. develops therapies to treat cancer. Its chimeric antigen receptor T-cell (CAR-T) therapy addresses the need to differentiate cancerous from non-cancerous tissues. The company was founded by Gideon Gross in April 2017 and is headquartered in Nes Ziona, Israel. | Health Technology |
GentiBio, Inc.
GentiBio, Inc. BiotechnologyHealth Technology GentiBio, Inc. engages in the development of engineered regulatory T cells (EngTregs) programmed to treat autoimmune, alloimmune, autoinflammatory, and allergic diseases. The company was founded by Adel Nada, David Rawlings, Jane H. Buckner, and Gideon Gross and is headquartered in Seattle, WA. | Health Technology |
- Stock Market
- Insiders
- Gideon Gross
- Experience
